AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Total publications: 518 Publications in international journals: 315 Cumulative impact factor: 902 Citations (Google Scholar): over 12,600 Independent citations (MTMT): 6,864 Hirsch index (Google Scholar): 55
=== Coupling CE with MALDI-MS === Off-line coupling of CE to MALDI, the CE effluent could be sprayed or added drop wise on MALDI target plate then dried and analyzed by MS. For online coupling, a moving target with continuous contact to CE capillary end is required. The moving target takes analytes into MS where it is desorbed and ionized. Musyimi et al. developed a new technique where rotating ball was used to transfer CE to MS. The sample from CE is mixed with matrix coming though another capillary. As the ball rotates the sample is dried before it reaches ionization region. This technique has high sensitivity since no makeup fluid is used.
=== Business and markets === As of January 2021, Tetra Pak was operating in over 160 countries through its 29 market companies. Between 2007 and 2010, the company saw growth in emerging markets and opened new plants to meet that demand. Tetra Pak invested €100 million to build a plant in Russia in 2007, and built a €60 million plant in China the following year. In 2009, the company announced that it would invest more than €200 million to build plants in India and Pakistan to serve emerging markets in Asia and the Middle East, where milk consumption was rising, especially of ultra-high-temperature processed milk. At the time, two-thirds of Tetra Pak's global sales came from dairy packaging.
==== T ==== Tapa – a Philippine food made dried or cured beef, mutton or venison, although other meats or even fish may be used. It is prepared using thin slices of meat that are cured with salt and spices as a method of preserving it. Tolkusha Tsamarella – a Cypriot traditional food. It consists of meat, usually goat meat, that is salted and cured for preservation. The process of preparation traditionally involves drying in the sun. Tyrolean Speck – a distinctively juniper-flavored ham originally from Tyrol, an historical region that since 1918 partially lies in Italy. Tyrolean speck is made from the hind leg of the pig, and is deboned before curing in salt and one of various spice combinations, which may include garlic, bay leaves, juniper berries, nutmeg, and other spices. It is then rested for a period of several weeks, after which, the smoking process begins. It is cold-smoked slowly and intermittently for two or three hours a day for a period of roughly a week using woods such as beech at temperatures that never exceed 20 °C (68 °F). It is then matured for five months.
Sources: en.wikipedia.org
=== Lipton Yellow Label === Lipton Yellow Label tea has been sold since 1890, when Sir Thomas Lipton introduced the first version of the yellow pack with a red Lipton shield that is still in use today. It is sold in 150 countries worldwide. Lipton Yellow Label is a blend of several types of tea, sold both in tea bags and as loose tea, rolled into small leaves like gunpowder green tea.
==== Mouse bioassay ==== The mouse bioassay (MBA) procedure developed by Yasumoto et al. is the official reference method used to analyse for YTX and lipophilic toxins including okadaic acid, dinophysistoxins (DSPs), azaspiracids, and pectenotoxins. The MBA involves injecting the extracted toxin into a mouse and monitoring the mouse survival rate; the toxicity of the sample can be subsequently deduced and the analyte concentration determined. This calculation is made on the basis that one mouse unit (MU) is the minimum quantity of toxin needed to kill a mouse in 24hours. The MU is set by regulating bodies at 0.05 MU/g of animal. The original Yasumoto MBA is subject to interferences from paralytic shellfish toxins and free fatty acids in solution, which cause false positive results. Several modifications to the MBA can be made to allow the test to be performed without these errors. The MBA, however, still has many drawbacks;
== Factors affecting ion exchange resin efficiency == The efficiency of ion exchange resins is influenced by a combination of physical, chemical, and operational factors. These variables determine how effectively the resin can exchange ions, maintain selectivity, and preserve its structural integrity over time. The structural properties of the resin are fundamental to its performance. Attributes such as particle size, internal porosity, and the degree of cross-linking control the accessibility of exchange sites. Smaller particles tend to offer faster ion exchange due to greater surface area, although they can also lead to increased resistance to flow in packed bed systems. Temperature is another key factor. In general, higher temperatures accelerate ion mobility and enhance exchange kinetics. However, prolonged exposure to elevated temperatures can degrade the resin's polymer matrix or functional groups, particularly in weakly acidic or basic resins. There are however, resins rated for higher temperatures (up to 120 °C) which employ reinforced polymer backbones to withstand thermal stress on the system. The pH of the solution directly affects the ionization state of both the resin and the solutes. While strong acid and strong base resins maintain their functionality across a wide pH range, weak resins may lose efficiency outside their optimal pH window. The pH also influences the speciation of certain ions, impacting their affinity for the resin. Ionic concentration determines the driving force for ion exchange.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.